Dr. Wang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Elm and Carlton St
Buffalo, NY 14263Phone+1 716-845-2300Fax+1 716-845-8741
Summary
- I am a hematologist-oncologist and physician scientist whose clinical practice focuses on the treatment of patients with acute and chronic leukemia, myeloid disorders, and benign hematological conditions.
Education & Training
- Memorial Sloan Kettering Cancer Center1999 - 2003
- Yale-New Haven Medical CenterResidency, Internal Medicine, 1997 - 1999
- Keck School of Medicine of the University of Southern CaliforniaClass of 1996
- Harvard UniversityBA, Biology, Cum Laude, 1987 - 1991
Certifications & Licensure
- NY State Medical License 1999 - 2025
Clinical Trials
- Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
- Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML Start of enrollment: 2014 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 67 citationsPhase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemiaHarry P. Erba, Pamela S. Becker, Paul J. Shami, Michael R. Grunwald, Donna L. Flesher
Blood Advances. 2019-07-09 - 44 citationsMagrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.David A Sallman, Monzr M Al Malki, Adam S Asch, Eunice S Wang, Joseph G Jurcic
Journal of Clinical Oncology. 2023-05-20 - 11 citationsTolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Re...Naval G Daver, Paresh Vyas, Suman Kambhampati, Monzr M Al Malki, Richard A Larson
Journal of Clinical Oncology. 2023-11-01
Journal Articles
- NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor OutcomeEunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature
Abstracts/Posters
- Mitophagy Plays a Key Role in the Anti-Leukemic Activity of Autophagy Inhibitors Under Hypoxia in Acute Myeloid LeukemiaEunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patient...Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leu...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- AML: Expert Guidance on Current Standards and New Directions in Patient Care61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid L...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- Study Highlights Promising New Treatment Option for Patients with Treatment-Resistant Acute Myeloid LeukemiaOctober 1st, 2024
- Biomarker Uncovered by Roswell Park Team Identifies NET Patients Likely to Have Blood Side Effects from PRRTJune 9th, 2021
- Roswell Park Researchers Gear up for ASCO 2021 Annual MeetingJune 3rd, 2021
- Join now to see all
Committees
- Member, Scientific Review Committee 2009 - Present
- Member, Fellowship Program Committee 2007 - Present
Professional Memberships
- Member
- Member
- Member
External Links
- roswellpark.orghttps://www.roswellpark.org/eunice-wang
- roswellpark.eduhttps://www.roswellpark.edu/eunice-wang
- buffalo.eduhttps://medicine.buffalo.edu/content/medicine/faculty/profile.html?ubit=ewang3
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: